Want to see GB:GSK full AI Analyst Report?
GSK Stock Chart & Stats
1919.50 p
17.50 p(0.91%)
At close: 4:00 PM EDT
1919.50 p
17.50 p(0.91%)
Day’s Range― - ―
52-Week Range1,288.60 p - 2,282.00 p
Previous CloseN/A
Volume794.16K
Average Volume (3M)8.54M
Market Cap
£77.40B
Enterprise Value95.13K
Total Cash (Recent Filing)£3.11B
Total Debt (Recent Filing)£18.24B
Price to Earnings (P/E)16.1
Beta1.06
Next Earnings
Oct 28, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield3.47%
Share Statistics
EPS (TTM)1.20
Shares Outstanding4,045,395,300
10 Day Avg. Volume6,837,178
30 Day Avg. Volume8,542,213
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,135.85Price Target Upside11.27% Upside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)1.78
Revenue Forecast (FY)£33.85B
Bulls Say, Bears Say
Bulls Say
High Profitability And Cash GenerationSustained high gross and operating margins with strong trailing‑12M operating and free cash flow create a durable funding base for R&D, dividends and strategic reinvestment. Reliable cash generation supports long‑term product development and shareholder returns even through cyclical softness.
Late‑stage Pipeline And R&D ReallocationConcentrating capital and talent on 7 late‑stage assets and initiating 20+ phase III trials increases probability of new product inflows over the medium term. The Accelerate Growth plan reallocates savings into R&D, boosting structural product replacement potential and future revenue resilience.
Strengthened Equity Base With High ROEA materially stronger equity base and robust return on equity indicate improved balance‑sheet resilience and capital efficiency. This bolsters the company's ability to fund acquisitions, absorb shocks, and invest in growth initiatives without solely relying on external borrowing.
Bears Say
Elevated LeverageMeaningful leverage increases exposure to interest‑rate and refinancing risk and limits strategic flexibility. In a sector with cyclical approvals and lumpy launches, elevated debt raises the cost of managing setbacks and can constrain M&A or R&D pacing if profitability weakens.
Uneven Earnings And Cash ConversionInconsistent conversion of earnings to free cash flow reduces predictability of funds available for R&D, dividends and buybacks. Persistent volatility forces tougher capital allocation choices and increases execution risk for multi‑year programs that depend on steady internal funding.
Loss‑of‑exclusivity Risk (dolutegravir)Dolutegravir patent expiry presents structural top‑line and margin pressure in core HIV revenues absent successful product replacements. The planned savings and reinvestment help, but execution risk remains: late‑stage launches must materialize to replace lost exclusivity and pricing power.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1288.60 p and its highest was 2282.00 p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £77.40B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 28, 2026 which is in 85 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 28, 2026. The company reported 0.505 p earnings per share for the quarter, beating the consensus estimate of 0.465 p by 0.04 p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of 17 p which represents an annual dividend yield of 3.47%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.52.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,045,395,300 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.505 p in its last earnings report, beating expectations of 0.465 p. Following the earnings report the stock price went up 3.468%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£2,135.85 (11.27% Upside)
£2,135.85 (11.27% Upside)
Blogger Sentiment
Neutral
GB:GSK Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth £744.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.62%
12-Months-Change
Fundamentals
Return on Equity
3.47%
Trailing 12-Months
Asset Growth
3.56%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
GSK Stock 12 Month Forecast
Average Price Target
2,135.85 p
▲(11.27% Upside)
Technical Analysis
AstraZeneca
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―










